Serving To Educate Primary Care Clinicians On Respiratory Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Metabolic Diseases Header 4

Clinical Practice Research Opportunity

GPRI, a Dutch research institute led by Prof. Janwillem Kocks, is setting up a new multi-country qualitative study, and we are looking for a medical professional in the United States to help us navigate country-specific activities, such as ethical approval and recruitment of pharmacies. Furthermore, to aid in the interpretation of the results, and join the publication and conference abstracts that follow from these results.

Study: Impact of Asthma

Design: Multi-country, Qualitative

Coordinator: Prof. Janwillem Kocks, GPRI, the Netherlands

Aim: To evaluate the impact of Acute Worsening Events on daily lives of patients with asthma

Recruitment through: Pharmacies

Target: 40 participants in the United States

Study duration: For participant, 13 – 17 weeks

First subject in: For the USA, aiming at February 2024.

Looking for: Medical professional to assist in country-specific ethical approval and recruitment of pharmacies.

Compensation: We project an investment of 19 hours, which is compensated at $200/hour.

Contact if interested: Yoran Gerritsma at


Study background: CompEx, a composite outcome for the evaluation of new asthma therapies, is defined as the first occurrence of an Acute Worsening Event or a severe exacerbation. CompEx events are ~3 times more likely than severe exacerbations (Fuhlbrigge et al., 2017) and, when used as primary outcome for trials, could allow for shorter trials that require fewer patients. An Acute Worsening Event is based on diary events (filled in twice daily, takes <10 minutes), capturing Peak Expiratory Flow (PEF), amount of reliever use, and a 1-item questionnaire on symptoms. In this study, we evaluate the impact of an Acute Worsening Event on the daily lives of patients with asthma through semi-structured interviews.

Fuhlbrigge A. et al., (2017). A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials. The Lancet Respiratory Medicine, 5(7), 577–590.